SIMILAR PATTERNS OF AMINO ACIDS FOR 4V04_A_0LIA1772_1

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1h4l	CELL DIVISION PROTEIN KINASE 5 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 18 ALA A 31 GLU A 51 CYH A 117 HIS A 124 ALA A 143	None	1.26A	4v04A-1h4lA: 17.9	4v04A-1h4lA: 27.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1luf	MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK (Rattus norvegicus)	PF07714 (Pkinase_Tyr)	6	VAL A 588 ALA A 606 LEU A 715 HIS A 722 ALA A 741 ASP A 742	None	0.80A	4v04A-1lufA: 33.6	4v04A-1lufA: 38.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	VAL A 275 ALA A 288 GLU A 305 HIS A 380 ALA A 399 GLY A 402	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) None P16 A 2 (-3.5A) None	1.08A	4v04A-1opkA: 29.6	4v04A-1opkA: 27.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	VAL A 275 ALA A 288 GLU A 305 LEU A 373 HIS A 380 ALA A 399	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) None None P16 A 2 (-3.5A)	0.63A	4v04A-1opkA: 29.6	4v04A-1opkA: 27.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1py5	TGF-BETA RECEPTOR TYPE I (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	6	VAL A 219 ALA A 230 GLU A 245 HIS A 331 ALA A 350 GLY A 353	PY1 A 700 ( 4.7A) PY1 A 700 (-3.5A) PY1 A 700 ( 4.9A) None PY1 A 700 ( 4.2A) None	0.91A	4v04A-1py5A: 20.7	4v04A-1py5A: 29.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1py5	TGF-BETA RECEPTOR TYPE I (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	6	VAL A 219 ALA A 230 GLU A 245 LEU A 316 HIS A 331 ALA A 350	PY1 A 700 ( 4.7A) PY1 A 700 (-3.5A) PY1 A 700 ( 4.9A) None None PY1 A 700 ( 4.2A)	0.63A	4v04A-1py5A: 20.7	4v04A-1py5A: 29.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1q8y	SR PROTEIN KINASE (Saccharomyces cerevisiae)	PF00069 (Pkinase)	6	VAL A 172 ALA A 185 GLU A 202 HIS A 292 ALA A 549 GLY A 552	ADP A 810 (-4.1A) ADP A 810 (-3.3A) None None None None	1.35A	4v04A-1q8yA: 20.2	4v04A-1q8yA: 24.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 624 ALA A 642 GLU A 661 MET A 664 LEU A 802 CYH A 807	None	1.07A	4v04A-1rjbA: 32.8	4v04A-1rjbA: 45.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 624 ALA A 642 GLU A 661 MET A 664 LEU A 802 HIS A 809	None	0.90A	4v04A-1rjbA: 32.8	4v04A-1rjbA: 45.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 603 ALA A 621 GLU A 640 LEU A 783 CYH A 788 HIS A 790 ASP A 810	STI A 3 ( 4.6A) STI A 3 (-3.5A) STI A 3 (-3.6A) None STI A 3 (-2.8A) STI A 3 (-4.5A) STI A 3 (-3.9A)	0.68A	4v04A-1t46A: 34.3	4v04A-1t46A: 48.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1u59	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 352 ALA A 367 GLU A 386 ALA A 417 LEU A 452 HIS A 459	STU A 100 (-4.8A) STU A 100 (-3.2A) None STU A 100 (-3.7A) None None	0.73A	4v04A-1u59A: 30.2	4v04A-1u59A: 35.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 98 ALA A 111 MET A 132 LEU A 196 HIS A 203 ASP A 226	None	1.00A	4v04A-2ac5A: 19.0	4v04A-2ac5A: 26.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 98 GLU A 129 MET A 132 LEU A 196 HIS A 203 ASP A 226	None	1.25A	4v04A-2ac5A: 19.0	4v04A-2ac5A: 26.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2eu9	DUAL SPECIFICITY PROTEIN KINASE CLK3 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 170 ALA A 184 GLU A 201 HIS A 281 ALA A 319 GLY A 322	None	1.32A	4v04A-2eu9A: 21.2	4v04A-2eu9A: 24.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2eu9	DUAL SPECIFICITY PROTEIN KINASE CLK3 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 170 ALA A 184 GLU A 201 LEU A 274 HIS A 281 ALA A 319	None	0.88A	4v04A-2eu9A: 21.2	4v04A-2eu9A: 24.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 259 ALA A 271 GLU A 288 HIS A 362 ALA A 381 GLY A 384	1BM A 499 ( 4.8A) 1BM A 499 (-3.6A) 1BM A 499 (-3.2A) None 1BM A 499 ( 3.7A) None	1.33A	4v04A-2hk5A: 24.4	4v04A-2hk5A: 38.59
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 269 GLU A 286 LEU A 354 HIS A 361 ALA A 380 ASP A 381	GIN A 600 (-3.1A) GIN A 600 (-3.6A) GIN A 600 ( 4.6A) GIN A 600 (-4.3A) GIN A 600 (-3.1A) GIN A 600 (-4.9A)	1.01A	4v04A-2hz0A: 29.6	4v04A-2hz0A: 40.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2jgz	CELL DIVISION PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 18 ALA A 31 GLU A 51 CYH A 118 HIS A 125 ALA A 144	None	1.11A	4v04A-2jgzA: 22.6	4v04A-2jgzA: 25.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 259 ALA A 271 GLU A 288 HIS A 362 ALA A 381 ASP A 382	None 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.6A) None 1N8 A 501 ( 3.3A) 1N8 A 501 ( 3.3A)	0.65A	4v04A-2og8A: 30.8	4v04A-2og8A: 38.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 596 ALA A 614 GLU A 633 LEU A 769 CYH A 774 HIS A 776	None	0.60A	4v04A-2ogvA: 33.1	4v04A-2ogvA: 47.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ozo	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	6	VAL A 352 ALA A 367 ALA A 417 LEU A 452 HIS A 459 GLY A 481	ANP A 615 (-4.5A) ANP A 615 (-3.3A) ANP A 615 (-3.9A) None None None	0.74A	4v04A-2ozoA: 27.8	4v04A-2ozoA: 21.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 838 ALA A 853 ALA A 905 LEU A 955 HIS A 962 ALA A 981 ASP A 982	MR9 A 301 (-4.6A) MR9 A 301 (-3.5A) MR9 A 301 (-3.6A) MR9 A 301 (-4.4A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A)	0.55A	4v04A-2p4iA: 25.4	4v04A-2p4iA: 42.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2psq	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	VAL A 495 ALA A 515 GLU A 534 MET A 537 VAL A 564 ALA A 567 LEU A 617 CYH A 622 HIS A 624 ALA A 643	None	0.65A	4v04A-2psqA: 36.0	4v04A-2psqA: 73.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2psq	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 495 ALA A 515 GLU A 534 VAL A 564 ALA A 567 HIS A 624 ALA A 643 GLY A 646	None	1.20A	4v04A-2psqA: 36.0	4v04A-2psqA: 73.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qlu	ACTIVIN RECEPTOR TYPE IIB (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 204 ALA A 215 GLU A 230 LEU A 301 HIS A 319 ALA A 338	ADE A 488 ( 4.9A) ADE A 488 (-3.2A) None None None None	0.95A	4v04A-2qluA: 24.2	4v04A-2qluA: 26.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2vk4	PYRUVATE DECARBOXYLASE (Kluyveromyces lactis)	PF00205 (TPP_enzyme_M) PF02775 (TPP_enzyme_C) PF02776 (TPP_enzyme_N)	6	ALA A 218 GLU A 230 VAL A 285 ALA A 220 LEU A 189 ASP A 226	None	1.19A	4v04A-2vk4A: undetectable	4v04A-2vk4A: 20.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2xik	SERINE/THREONINE PROTEIN KINASE 25 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 34 ALA A 47 GLU A 66 LEU A 131 HIS A 138 ALA A 157	J60 A1294 ( 4.9A) J60 A1294 (-3.3A) None None None J60 A1294 ( 4.2A)	0.63A	4v04A-2xikA: 18.5	4v04A-2xikA: 27.38
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	7	VAL A 261 ALA A 273 GLU A 290 HIS A 365 ALA A 384 ASP A 385 GLY A 387	None	1.41A	4v04A-2zv7A: 30.7	4v04A-2zv7A: 38.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 495 ALA A 515 GLU A 534 MET A 537 VAL A 564 ALA A 567 LEU A 617 CYH A 622	M33 A1996 ( 4.7A) M33 A1996 (-3.3A) None None None M33 A1996 (-3.8A) None None	0.91A	4v04A-3b2tA: 27.9	4v04A-3b2tA: 86.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 495 ALA A 515 GLU A 534 VAL A 564 ALA A 567 HIS A 624 GLY A 646	M33 A1996 ( 4.7A) M33 A1996 (-3.3A) None None M33 A1996 (-3.8A) None None	1.43A	4v04A-3b2tA: 27.9	4v04A-3b2tA: 86.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 495 ALA A 515 GLU A 534 VAL A 564 ALA A 567 LEU A 617 CYH A 622 HIS A 624	M33 A1996 ( 4.7A) M33 A1996 (-3.3A) None None M33 A1996 (-3.8A) None None None	0.78A	4v04A-3b2tA: 27.9	4v04A-3b2tA: 86.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 495 ALA A 515 MET A 537 VAL A 564 ALA A 567 LEU A 617 CYH A 622 ALA A 643	M33 A1996 ( 4.7A) M33 A1996 (-3.3A) None None M33 A1996 (-3.8A) None None None	0.77A	4v04A-3b2tA: 27.9	4v04A-3b2tA: 86.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 495 ALA A 515 VAL A 564 ALA A 567 HIS A 624 ALA A 643 GLY A 646	M33 A1996 ( 4.7A) M33 A1996 (-3.3A) None M33 A1996 (-3.8A) None None None	1.13A	4v04A-3b2tA: 27.9	4v04A-3b2tA: 86.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 495 ALA A 515 VAL A 564 ALA A 567 LEU A 617 CYH A 622 HIS A 624 ALA A 643	M33 A1996 ( 4.7A) M33 A1996 (-3.3A) None M33 A1996 (-3.8A) None None None None	0.52A	4v04A-3b2tA: 27.9	4v04A-3b2tA: 86.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3bhh	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE II BETA CHAIN (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 28 ALA A 41 GLU A 61 CYH A 127 HIS A 134 ALA A 156	5CP A 600 ( 4.4A) 5CP A 600 (-3.6A) None None None 5CP A 600 ( 3.9A)	1.27A	4v04A-3bhhA: 22.6	4v04A-3bhhA: 26.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3c1x	HEPATOCYTE GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A1108 GLU A1127 LEU A1195 HIS A1202 ALA A1221 ASP A1222	CKK A1500 (-3.2A) CKK A1500 (-3.4A) CKK A1500 (-4.4A) CKK A1500 (-4.2A) CKK A1500 (-3.4A) CKK A1500 (-4.5A)	0.85A	4v04A-3c1xA: 25.9	4v04A-3c1xA: 32.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3c4f	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	11	VAL A 492 ALA A 512 GLU A 531 MET A 534 VAL A 561 ALA A 564 LEU A 614 CYH A 619 HIS A 621 ALA A 640 GLY A 643	None C4F A 1 (-3.3A) None None C4F A 1 ( 4.8A) C4F A 1 (-3.5A) None None None C4F A 1 (-3.6A) None	0.55A	4v04A-3c4fA: 42.7	4v04A-3c4fA: 99.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3dak	SERINE/THREONINE-PRO TEIN KINASE OSR1 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 31 ALA A 44 LEU A 137 HIS A 144 ALA A 163 GLY A 166	ANP A 1 (-4.5A) ANP A 1 ( 3.9A) None None MG A 296 ( 3.9A) None	0.71A	4v04A-3dakA: 21.3	4v04A-3dakA: 30.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3e7o	MITOGEN-ACTIVATED PROTEIN KINASE 9 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 40 ALA A 53 GLU A 73 LEU A 142 HIS A 149 ASP A 169	35F A 1 ( 4.8A) 35F A 1 (-3.6A) None None None None	0.98A	4v04A-3e7oA: 19.6	4v04A-3e7oA: 25.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3hng	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 841 ALA A 859 GLU A 878 VAL A 909 LEU A1013 CYH A1018 HIS A1020 ASP A1040	8ST A2001 ( 4.6A) 8ST A2001 ( 3.8A) 8ST A2001 (-3.7A) 8ST A2001 (-4.1A) 8ST A2001 (-4.6A) 8ST A2001 ( 4.7A) 8ST A2001 ( 4.8A) None	0.60A	4v04A-3hngA: 34.2	4v04A-3hngA: 47.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3hu5	ISOCHORISMATASE FAMILY PROTEIN (Desulfovibrio vulgaris)	PF00857 (Isochorismatase)	6	VAL A 56 ALA A 12 VAL A 131 ALA A 10 ALA A 147 ASP A 146	None	1.22A	4v04A-3hu5A: undetectable	4v04A-3hu5A: 22.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3iec	SERINE/THREONINE-PRO TEIN KINASE MARK2 (Homo sapiens)	PF00069 (Pkinase) PF00627 (UBA)	7	VAL A 67 ALA A 80 ALA A 132 HIS A 173 ALA A 192 ASP A 193 GLY A 195	None	1.35A	4v04A-3iecA: 22.3	4v04A-3iecA: 27.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3lm5	SERINE/THREONINE-PRO TEIN KINASE 17B (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 47 ALA A 60 GLU A 80 ALA A 113 LEU A 149 HIS A 156	QUE A 1 ( 4.6A) QUE A 1 (-3.2A) QUE A 1 (-3.1A) QUE A 1 (-3.9A) None None	0.86A	4v04A-3lm5A: 23.3	4v04A-3lm5A: 23.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mdy	BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (Homo sapiens)	PF07714 (Pkinase_Tyr) PF08515 (TGF_beta_GS)	6	VAL A 218 ALA A 229 GLU A 244 HIS A 330 ALA A 349 GLY A 352	LDN A 1 ( 4.8A) LDN A 1 (-3.6A) None None LDN A 1 ( 3.8A) None	1.30A	4v04A-3mdyA: 24.8	4v04A-3mdyA: 26.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mdy	BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (Homo sapiens)	PF07714 (Pkinase_Tyr) PF08515 (TGF_beta_GS)	6	VAL A 218 ALA A 229 GLU A 244 LEU A 315 HIS A 330 ALA A 349	LDN A 1 ( 4.8A) LDN A 1 (-3.6A) None None None LDN A 1 ( 3.8A)	0.90A	4v04A-3mdyA: 24.8	4v04A-3mdyA: 26.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3my0	SERINE/THREONINE-PRO TEIN KINASE RECEPTOR R3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 216 ALA A 227 HIS A 328 ALA A 347 ASP A 348 GLY A 350	LDN A 600 (-4.5A) LDN A 600 (-3.2A) None LDN A 600 ( 3.8A) None None	0.93A	4v04A-3my0A: 24.1	4v04A-3my0A: 30.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3my0	SERINE/THREONINE-PRO TEIN KINASE RECEPTOR R3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 216 ALA A 227 LEU A 313 HIS A 328 ALA A 347 ASP A 348	LDN A 600 (-4.5A) LDN A 600 (-3.2A) None None LDN A 600 ( 3.8A) None	1.12A	4v04A-3my0A: 24.1	4v04A-3my0A: 30.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nuu	PKB-LIKE (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 109 GLU A 130 ALA A 162 HIS A 203 ASP A 223 GLY A 225	JOZ A 361 (-3.4A) SO4 A 5 (-3.1A) JOZ A 361 (-3.8A) None SO4 A 5 ( 4.5A) SO4 A 5 ( 4.6A)	1.35A	4v04A-3nuuA: 22.9	4v04A-3nuuA: 26.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nuu	PKB-LIKE (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 96 ALA A 109 GLU A 130 ALA A 162 HIS A 203 GLY A 225	JOZ A 361 ( 4.7A) JOZ A 361 (-3.4A) SO4 A 5 (-3.1A) JOZ A 361 (-3.8A) None SO4 A 5 ( 4.6A)	1.17A	4v04A-3nuuA: 22.9	4v04A-3nuuA: 26.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nuu	PKB-LIKE (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 96 ALA A 109 GLU A 130 ALA A 162 LEU A 196 HIS A 203	JOZ A 361 ( 4.7A) JOZ A 361 (-3.4A) SO4 A 5 (-3.1A) JOZ A 361 (-3.8A) None None	0.71A	4v04A-3nuuA: 22.9	4v04A-3nuuA: 26.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pls	MACROPHAGE-STIMULATI NG PROTEIN RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A1096 ALA A1112 LEU A1199 HIS A1206 ALA A1225 GLY A1228	ANP A1358 (-4.4A) ANP A1358 ( 3.8A) None None None None	0.72A	4v04A-3plsA: 30.2	4v04A-3plsA: 39.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3q4t	ACTIVIN RECEPTOR TYPE-2A (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 206 ALA A 217 GLU A 232 LEU A 303 HIS A 320 ALA A 339	TAK A 2 ( 4.9A) TAK A 2 (-3.5A) TAK A 2 ( 4.9A) None None TAK A 2 ( 4.2A)	1.01A	4v04A-3q4tA: 23.6	4v04A-3q4tA: 26.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3tt0	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	11	VAL A 492 ALA A 512 GLU A 531 MET A 534 VAL A 561 ALA A 564 LEU A 614 CYH A 619 HIS A 621 ALA A 640 GLY A 643	07J A 1 (-4.0A) 07J A 1 (-3.5A) 07J A 1 (-3.8A) None 07J A 1 (-4.7A) 07J A 1 (-3.8A) None None None 07J A 1 (-3.2A) None	0.56A	4v04A-3tt0A: 41.1	4v04A-3tt0A: 92.24
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3vid	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 848 ALA A 866 GLU A 885 VAL A 916 LEU A1019 CYH A1024 ASP A1046	4TT A2001 ( 4.5A) 4TT A2001 (-3.5A) None None None None None	0.75A	4v04A-3vidA: 34.7	4v04A-3vidA: 49.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3vid	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 848 ALA A 866 GLU A 885 VAL A 916 LEU A1019 HIS A1026 ASP A1046	4TT A2001 ( 4.5A) 4TT A2001 (-3.5A) None None None None None	0.47A	4v04A-3vidA: 34.7	4v04A-3vidA: 49.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3wzd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 848 ALA A 866 GLU A 885 VAL A 916 LEU A1019 CYH A1024 HIS A1026	LEV A1201 ( 4.9A) LEV A1201 (-3.5A) LEV A1201 (-3.7A) LEV A1201 ( 4.6A) None DTT A1202 (-2.0A) None	0.47A	4v04A-3wzdA: 34.6	4v04A-3wzdA: 54.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4agd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 848 ALA A 866 GLU A 885 VAL A 916 LEU A1019 CYH A1024	None B49 A2000 (-3.5A) None B49 A2000 (-4.8A) None None	0.82A	4v04A-4agdA: 34.6	4v04A-4agdA: 49.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4agd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 848 ALA A 866 GLU A 885 VAL A 916 LEU A1019 HIS A1026 ASP A1046	None B49 A2000 (-3.5A) None B49 A2000 (-4.8A) None None None	0.71A	4v04A-4agdA: 34.6	4v04A-4agdA: 49.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ckr	EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 624 ALA A 653 GLU A 672 LEU A 757 HIS A 764 ALA A 783 ASP A 784	DI1 A1000 (-4.8A) DI1 A1000 (-3.6A) DI1 A1000 (-3.8A) DI1 A1000 (-4.4A) DI1 A1000 (-3.8A) DI1 A1000 (-3.7A) DI1 A1000 (-4.1A)	0.66A	4v04A-4ckrA: 30.6	4v04A-4ckrA: 37.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4crs	SERINE/THREONINE-PRO TEIN KINASE N2 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	VAL A 671 ALA A 684 GLU A 705 ALA A 740 ALA A 799 GLY A 802	AGS A1985 (-4.6A) AGS A1985 (-3.5A) None AGS A1985 (-3.9A) AGS A1985 ( 4.5A) None	1.29A	4v04A-4crsA: 15.0	4v04A-4crsA: 28.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4crs	SERINE/THREONINE-PRO TEIN KINASE N2 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	VAL A 671 ALA A 684 GLU A 705 ALA A 740 LEU A 773 ALA A 799	AGS A1985 (-4.6A) AGS A1985 (-3.5A) None AGS A1985 (-3.9A) None AGS A1985 ( 4.5A)	0.75A	4v04A-4crsA: 15.0	4v04A-4crsA: 28.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4e93	TYROSINE-PROTEIN KINASE FES/FPS (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	6	VAL A 575 ALA A 588 GLU A 607 LEU A 674 CYH A 679 HIS A 681	GUI A 901 (-4.5A) GUI A 901 (-3.4A) None None None None	1.01A	4v04A-4e93A: 32.1	4v04A-4e93A: 33.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f4p	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 385 ALA A 400 GLU A 420 ALA A 451 HIS A 492 GLY A 514	0SB A 701 (-4.0A) 0SB A 701 (-3.3A) None 0SB A 701 (-4.0A) None None	1.32A	4v04A-4f4pA: 25.9	4v04A-4f4pA: 36.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fl3	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	6	VAL A 385 ALA A 400 ALA A 451 LEU A 485 HIS A 492 GLY A 514	ANP A 701 (-4.1A) ANP A 701 (-3.3A) ANP A 701 (-4.1A) None None None	0.88A	4v04A-4fl3A: 29.1	4v04A-4fl3A: 21.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fr4	SERINE/THREONINE-PRO TEIN KINASE 32A (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 37 ALA A 50 GLU A 71 VAL A 100 LEU A 137 HIS A 144	STU A 401 ( 4.9A) STU A 401 (-3.2A) None None None None	0.79A	4v04A-4fr4A: 13.2	4v04A-4fr4A: 23.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hvi	TYROSINE-PROTEIN KINASE JAK3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 836 ALA A 853 GLU A 871 LEU A 940 CYH A 945 HIS A 947 ALA A 966	19S A1201 (-4.4A) 19S A1201 (-3.3A) None None None None 19S A1201 ( 4.1A)	0.73A	4v04A-4hviA: 29.2	4v04A-4hviA: 35.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 506 VAL A 555 ALA A 558 HIS A 615 ALA A 634 ASP A 635 GLY A 637	ACP A 801 (-3.3A) ACP A 801 (-4.7A) ACP A 801 (-3.7A) None None MG A 802 ( 3.0A) None	1.36A	4v04A-4k33A: 29.3	4v04A-4k33A: 80.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 486 ALA A 506 GLU A 525 MET A 528 VAL A 555 ALA A 558 LEU A 608 ALA A 634	ACP A 801 (-4.2A) ACP A 801 (-3.3A) ACP A 801 ( 4.8A) None ACP A 801 (-4.7A) ACP A 801 (-3.7A) None None	0.82A	4v04A-4k33A: 29.3	4v04A-4k33A: 80.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 486 ALA A 506 GLU A 525 VAL A 555 ALA A 558 HIS A 615 ALA A 634 GLY A 637	ACP A 801 (-4.2A) ACP A 801 (-3.3A) ACP A 801 ( 4.8A) ACP A 801 (-4.7A) ACP A 801 (-3.7A) None None None	1.26A	4v04A-4k33A: 29.3	4v04A-4k33A: 80.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 486 ALA A 506 GLU A 525 VAL A 555 ALA A 558 LEU A 608 HIS A 615 ALA A 634	ACP A 801 (-4.2A) ACP A 801 (-3.3A) ACP A 801 ( 4.8A) ACP A 801 (-4.7A) ACP A 801 (-3.7A) None None None	0.70A	4v04A-4k33A: 29.3	4v04A-4k33A: 80.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o27	SERINE/THREONINE-PRO TEIN KINASE 24 (Homo sapiens)	PF00069 (Pkinase)	6	VAL B 38 ALA B 51 GLU B 70 HIS B 142 ALA B 161 GLY B 164	ADP B 500 (-4.5A) ADP B 500 (-3.3A) None None None None	1.24A	4v04A-4o27B: 24.2	4v04A-4o27B: 28.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o27	SERINE/THREONINE-PRO TEIN KINASE 24 (Homo sapiens)	PF00069 (Pkinase)	6	VAL B 38 ALA B 51 GLU B 70 LEU B 135 HIS B 142 ALA B 161	ADP B 500 (-4.5A) ADP B 500 (-3.3A) None None None None	0.60A	4v04A-4o27B: 24.2	4v04A-4o27B: 28.61
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4rt7	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 624 ALA A 642 GLU A 661 MET A 664 LEU A 802 CYH A 807	None P30 A1001 (-3.4A) P30 A1001 (-3.6A) P30 A1001 ( 4.5A) None None	0.96A	4v04A-4rt7A: 28.4	4v04A-4rt7A: 40.49
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4rt7	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 624 ALA A 642 GLU A 661 MET A 664 LEU A 802 HIS A 809 ASP A 829	None P30 A1001 (-3.4A) P30 A1001 (-3.6A) P30 A1001 ( 4.5A) None P30 A1001 ( 4.3A) None	0.84A	4v04A-4rt7A: 28.4	4v04A-4rt7A: 40.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4tr2	SUBTILISIN-LIKE 1 SERINE PROTEASE (Plasmodium vivax)	PF00082 (Peptidase_S8)	6	ALA A 293 ALA A 528 LEU A 399 ALA A 557 ASP A 394 GLY A 395	None	1.26A	4v04A-4tr2A: undetectable	4v04A-4tr2A: 19.49
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	7	VAL A 22 ALA A 35 GLU A 52 HIS A 127 ALA A 146 ASP A 147 GLY A 149	ACP A1264 (-4.7A) ACP A1264 (-2.9A) None None None None None	1.36A	4v04A-4ueuA: 30.3	4v04A-4ueuA: 41.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4uy9	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 158 ALA A 169 ALA A 223 LEU A 256 HIS A 266 GLY A 296	None	0.72A	4v04A-4uy9A: 26.7	4v04A-4uy9A: 31.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xcu	FIBROBLAST GROWTH FACTOR RECEPTOR 4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	VAL A 481 ALA A 501 GLU A 520 VAL A 550 ALA A 553 LEU A 603 CYH A 608 HIS A 610 ALA A 629 GLY A 632	40M A1002 ( 4.5A) 40M A1002 ( 4.1A) 40M A1002 (-3.7A) 40M A1002 (-4.7A) 40M A1002 (-3.7A) None None None 40M A1002 (-3.0A) None	0.38A	4v04A-4xcuA: 38.9	4v04A-4xcuA: 73.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xuf	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 624 ALA A 642 GLU A 661 MET A 664 LEU A 802 HIS A 809 ASP A 829	P30 A1001 ( 4.8A) P30 A1001 (-3.5A) P30 A1001 (-3.1A) P30 A1001 (-3.9A) None P30 A1001 (-4.4A) None	0.69A	4v04A-4xufA: 24.2	4v04A-4xufA: 49.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yff	SERINE/THREONINE-PRO TEIN KINASE TNNI3K (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 477 ALA A 488 GLU A 509 LEU A 577 HIS A 586 ALA A 605	None 4CV A 801 (-3.5A) None None None 4CV A 801 ( 3.9A)	0.94A	4v04A-4yffA: 24.6	4v04A-4yffA: 28.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5a46	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B (Homo sapiens)	PF07714 (Pkinase_Tyr)	11	VAL A 492 ALA A 512 GLU A 531 MET A 534 VAL A 561 ALA A 564 LEU A 614 CYH A 619 HIS A 621 ALA A 640 GLY A 643	38O A1769 (-4.5A) 38O A1769 (-3.6A) EDO A1766 (-4.1A) None 38O A1769 (-4.3A) 38O A1769 (-3.9A) None None None EDO A1766 ( 4.4A) EDO A1766 (-3.6A)	0.23A	4v04A-5a46A: 43.5	4v04A-5a46A: 98.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5dbx	STE20/SPS1-RELATED PROLINE-ALANINE-RICH PROTEIN KINASE (Mus musculus)	PF00069 (Pkinase)	6	VAL A 89 ALA A 102 LEU A 195 HIS A 202 ALA A 221 GLY A 224	ANP A 401 (-4.0A) ANP A 401 ( 4.0A) None None MG A 402 ( 4.6A) None	0.89A	4v04A-5dbxA: 20.7	4v04A-5dbxA: 28.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5es1	MAP/MICROTUBULE AFFINITY-REGULATING KINASE 4 (Homo sapiens)	PF00069 (Pkinase) PF00627 (UBA)	6	VAL A 70 ALA A 83 GLU A 103 ALA A 135 HIS A 176 ALA A 195	5RC A4000 (-4.6A) 5RC A4000 (-3.6A) None 5RC A4000 (-3.7A) None 5RC A4000 ( 3.9A)	0.79A	4v04A-5es1A: 22.4	4v04A-5es1A: 28.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5fm2	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 738 ALA A 756 GLU A 775 VAL A 804 ALA A 807 LEU A 865 HIS A 872	PP1 A2012 (-4.4A) PP1 A2012 (-3.2A) PP1 A2012 (-3.5A) PP1 A2012 (-4.5A) PP1 A2012 ( 3.5A) None None	0.90A	4v04A-5fm2A: 33.7	4v04A-5fm2A: 51.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 607 ALA A 625 GLU A 644 LEU A 809 CYH A 814 HIS A 816 ASP A 836	748 A1001 ( 4.7A) 748 A1001 (-3.7A) 748 A1001 (-3.3A) 748 A1001 ( 4.6A) 748 A1001 (-3.4A) 748 A1001 (-3.8A) 748 A1001 (-4.8A)	0.62A	4v04A-5grnA: 25.8	4v04A-5grnA: 46.09
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5hes	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 30 ALA A 43 ALA A 85 LEU A 121 HIS A 131 GLY A 153	032 A 401 (-4.4A) 032 A 401 (-3.2A) 032 A 401 (-3.6A) None None 032 A 401 (-3.6A)	0.68A	4v04A-5hesA: 25.7	4v04A-5hesA: 30.59
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5hor	HEPATOCYTE GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A1092 ALA A1108 LEU A1195 HIS A1202 ALA A1221 GLY A1224	63K A1401 (-4.9A) 63K A1401 (-3.5A) None None 63K A1401 (-3.3A) None	0.83A	4v04A-5horA: 26.0	4v04A-5horA: 35.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5hu3	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN (Drosophila melanogaster)	PF00069 (Pkinase)	6	VAL A 28 ALA A 41 GLU A 61 HIS A 134 ALA A 156 GLY A 159	ADP A 301 (-3.7A) ADP A 301 (-3.5A) None None ADP A 301 ( 4.8A) None	1.30A	4v04A-5hu3A: 22.7	4v04A-5hu3A: 24.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5idn	CYCLIN-DEPENDENT KINASE 8 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 35 ALA A 50 GLU A 66 ALA A 100 HIS A 149 ALA A 172 GLY A 175	6A7 A 401 ( 4.5A) 6A7 A 401 (-3.3A) FMT A 404 ( 4.2A) 6A7 A 401 (-3.7A) FMT A 403 (-4.6A) 6A7 A 401 ( 4.1A) FMT A 404 ( 4.3A)	1.41A	4v04A-5idnA: 15.5	4v04A-5idnA: 26.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5idn	CYCLIN-DEPENDENT KINASE 8 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 35 ALA A 50 GLU A 66 ALA A 100 LEU A 142 HIS A 149 ALA A 172	6A7 A 401 ( 4.5A) 6A7 A 401 (-3.3A) FMT A 404 ( 4.2A) 6A7 A 401 (-3.7A) None FMT A 403 (-4.6A) 6A7 A 401 ( 4.1A)	0.81A	4v04A-5idnA: 15.5	4v04A-5idnA: 26.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j5t	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 30 ALA A 43 GLU A 61 LEU A 127 HIS A 134 ALA A 153	6G2 A 901 ( 4.9A) 6G2 A 901 (-3.2A) None None None 6G2 A 901 ( 4.2A)	0.75A	4v04A-5j5tA: 21.0	4v04A-5j5tA: 24.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j5t	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 30 ALA A 43 GLU A 61 MET A 64 HIS A 134 ALA A 153	6G2 A 901 ( 4.9A) 6G2 A 901 (-3.2A) None None None 6G2 A 901 ( 4.2A)	0.99A	4v04A-5j5tA: 21.0	4v04A-5j5tA: 24.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5x2v	L-METHIONINE GAMMA-LYASE (Pseudomonas putida)	PF01053 (Cys_Met_Meta_PP)	6	VAL A 185 ALA A 160 LEU A 143 ALA A 167 ASP A 168 GLY A 171	None	1.25A	4v04A-5x2vA: undetectable	4v04A-5x2vA: 21.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5xv7	SERINE-ARGININE (SR) PROTEIN KINASE 1 (Homo sapiens)	no annotation	6	VAL A 94 ALA A 107 GLU A 124 HIS A 211 ALA A 496 GLY A 499	EMH A 705 ( 4.4A) EMH A 705 (-3.6A) None None EMH A 705 ( 4.0A) None	1.33A	4v04A-5xv7A: 20.3	4v04A-5xv7A: 13.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5xv7	SERINE-ARGININE (SR) PROTEIN KINASE 1 (Homo sapiens)	no annotation	6	VAL A 94 ALA A 107 GLU A 124 LEU A 203 HIS A 211 ALA A 496	EMH A 705 ( 4.4A) EMH A 705 (-3.6A) None None None EMH A 705 ( 4.0A)	0.65A	4v04A-5xv7A: 20.3	4v04A-5xv7A: 13.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ao5	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	no annotation	6	VAL A 41 ALA A 54 LEU A 137 HIS A 144 ALA A 163 GLY A 166	ANP A 501 (-4.4A) ANP A 501 ( 3.7A) None None None None	0.89A	4v04A-6ao5A: 22.0	4v04A-6ao5A: 24.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6b3e	CYCLIN-DEPENDENT KINASE 12 (Homo sapiens)	no annotation	6	VAL A 741 ALA A 754 GLU A 774 CYH A 850 HIS A 857 ALA A 876	None CJM A1102 (-3.1A) None None None CJM A1102 (-3.6A)	1.17A	4v04A-6b3eA: 22.1	4v04A-6b3eA: 16.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6c9d	SERINE/THREONINE-PRO TEIN KINASE MARK1,SERINE/THREONI NE-PROTEIN KINASE MARK1 (Homo sapiens)	no annotation	7	VAL A 74 ALA A 87 GLU A 107 ALA A 139 HIS A 180 ALA A 199 GLY A 202	None	1.33A	4v04A-6c9dA: 21.2	4v04A-6c9dA: 12.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fek	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET (Homo sapiens)	no annotation	7	VAL A 738 ALA A 756 GLU A 775 VAL A 804 ALA A 807 HIS A 872 GLY A 894	ADN A1104 (-4.4A) ADN A1104 (-3.4A) None ADN A1104 ( 4.6A) ADN A1104 (-3.6A) None None	1.45A	4v04A-6fekA: 32.7	4v04A-6fekA: 18.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fek	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET (Homo sapiens)	no annotation	7	VAL A 738 ALA A 756 GLU A 775 VAL A 804 ALA A 807 LEU A 865 HIS A 872	ADN A1104 (-4.4A) ADN A1104 (-3.4A) None ADN A1104 ( 4.6A) ADN A1104 (-3.6A) None None	0.78A	4v04A-6fekA: 32.7	4v04A-6fekA: 18.64

[["4V04_A_0LIA1772_1","1h4l","Homo sapiens","CELL DIVISION PROTEIN KINASE 5","PF00069(Pkinase)",6,"VAL A  18;ALA A  31;GLU A  51;CYH A 117;HIS A 124;ALA A 143","None","1.26A","4v04A-1h4lA:17.9","4v04A-1h4lA:27.11"],["4V04_A_0LIA1772_1","1luf","Rattus norvegicus","MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK","PF07714(Pkinase_Tyr)",6,"VAL A 588;ALA A 606;LEU A 715;HIS A 722;ALA A 741;ASP A 742","None","0.80A","4v04A-1lufA:33.6","4v04A-1lufA:38.15"],["4V04_A_0LIA1772_1","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"VAL A 275;ALA A 288;GLU A 305;HIS A 380;ALA A 399;GLY A 402","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);None;P16 A   2 (-3.5A);None","1.08A","4v04A-1opkA:29.6","4v04A-1opkA:27.68"],["4V04_A_0LIA1772_1","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"VAL A 275;ALA A 288;GLU A 305;LEU A 373;HIS A 380;ALA A 399","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);None;None;P16 A   2 (-3.5A)","0.63A","4v04A-1opkA:29.6","4v04A-1opkA:27.68"],["4V04_A_0LIA1772_1","1py5","Homo sapiens","TGF-BETA RECEPTOR TYPE I","PF00069(Pkinase);PF08515(TGF_beta_GS)",6,"VAL A 219;ALA A 230;GLU A 245;HIS A 331;ALA A 350;GLY A 353","PY1 A 700 ( 4.7A);PY1 A 700 (-3.5A);PY1 A 700 ( 4.9A);None;PY1 A 700 ( 4.2A);None","0.91A","4v04A-1py5A:20.7","4v04A-1py5A:29.30"],["4V04_A_0LIA1772_1","1py5","Homo sapiens","TGF-BETA RECEPTOR TYPE I","PF00069(Pkinase);PF08515(TGF_beta_GS)",6,"VAL A 219;ALA A 230;GLU A 245;LEU A 316;HIS A 331;ALA A 350","PY1 A 700 ( 4.7A);PY1 A 700 (-3.5A);PY1 A 700 ( 4.9A);None;None;PY1 A 700 ( 4.2A)","0.63A","4v04A-1py5A:20.7","4v04A-1py5A:29.30"],["4V04_A_0LIA1772_1","1q8y","Saccharomyces cerevisiae","SR PROTEIN KINASE","PF00069(Pkinase)",6,"VAL A 172;ALA A 185;GLU A 202;HIS A 292;ALA A 549;GLY A 552","ADP A 810 (-4.1A);ADP A 810 (-3.3A);None;None;None;None","1.35A","4v04A-1q8yA:20.2","4v04A-1q8yA:24.32"],["4V04_A_0LIA1772_1","1rjb","Homo sapiens","FL CYTOKINE RECEPTOR","PF07714(Pkinase_Tyr)",6,"VAL A 624;ALA A 642;GLU A 661;MET A 664;LEU A 802;CYH A 807","None","1.07A","4v04A-1rjbA:32.8","4v04A-1rjbA:45.95"],["4V04_A_0LIA1772_1","1rjb","Homo sapiens","FL CYTOKINE RECEPTOR","PF07714(Pkinase_Tyr)",6,"VAL A 624;ALA A 642;GLU A 661;MET A 664;LEU A 802;HIS A 809","None","0.90A","4v04A-1rjbA:32.8","4v04A-1rjbA:45.95"],["4V04_A_0LIA1772_1","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",7,"VAL A 603;ALA A 621;GLU A 640;LEU A 783;CYH A 788;HIS A 790;ASP A 810","STI A   3 ( 4.6A);STI A   3 (-3.5A);STI A   3 (-3.6A);None;STI A   3 (-2.8A);STI A   3 (-4.5A);STI A   3 (-3.9A)","0.68A","4v04A-1t46A:34.3","4v04A-1t46A:48.89"],["4V04_A_0LIA1772_1","1u59","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF07714(Pkinase_Tyr)",6,"VAL A 352;ALA A 367;GLU A 386;ALA A 417;LEU A 452;HIS A 459","STU A 100 (-4.8A);STU A 100 (-3.2A);None;STU A 100 (-3.7A);None;None","0.73A","4v04A-1u59A:30.2","4v04A-1u59A:35.64"],["4V04_A_0LIA1772_1","2ac5","Homo sapiens","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","PF00069(Pkinase)",6,"VAL A  98;ALA A 111;MET A 132;LEU A 196;HIS A 203;ASP A 226","None","1.00A","4v04A-2ac5A:19.0","4v04A-2ac5A:26.06"],["4V04_A_0LIA1772_1","2ac5","Homo sapiens","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","PF00069(Pkinase)",6,"VAL A  98;GLU A 129;MET A 132;LEU A 196;HIS A 203;ASP A 226","None","1.25A","4v04A-2ac5A:19.0","4v04A-2ac5A:26.06"],["4V04_A_0LIA1772_1","2eu9","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK3","PF00069(Pkinase)",6,"VAL A 170;ALA A 184;GLU A 201;HIS A 281;ALA A 319;GLY A 322","None","1.32A","4v04A-2eu9A:21.2","4v04A-2eu9A:24.93"],["4V04_A_0LIA1772_1","2eu9","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK3","PF00069(Pkinase)",6,"VAL A 170;ALA A 184;GLU A 201;LEU A 274;HIS A 281;ALA A 319","None","0.88A","4v04A-2eu9A:21.2","4v04A-2eu9A:24.93"],["4V04_A_0LIA1772_1","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",6,"VAL A 259;ALA A 271;GLU A 288;HIS A 362;ALA A 381;GLY A 384","1BM A 499 ( 4.8A);1BM A 499 (-3.6A);1BM A 499 (-3.2A);None;1BM A 499 ( 3.7A);None","1.33A","4v04A-2hk5A:24.4","4v04A-2hk5A:38.59"],["4V04_A_0LIA1772_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",6,"ALA A 269;GLU A 286;LEU A 354;HIS A 361;ALA A 380;ASP A 381","GIN A 600 (-3.1A);GIN A 600 (-3.6A);GIN A 600 ( 4.6A);GIN A 600 (-4.3A);GIN A 600 (-3.1A);GIN A 600 (-4.9A)","1.01A","4v04A-2hz0A:29.6","4v04A-2hz0A:40.20"],["4V04_A_0LIA1772_1","2jgz","Homo sapiens","CELL DIVISION PROTEIN KINASE 2","PF00069(Pkinase)",6,"VAL A  18;ALA A  31;GLU A  51;CYH A 118;HIS A 125;ALA A 144","None","1.11A","4v04A-2jgzA:22.6","4v04A-2jgzA:25.37"],["4V04_A_0LIA1772_1","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",6,"VAL A 259;ALA A 271;GLU A 288;HIS A 362;ALA A 381;ASP A 382","None;1N8 A 501 ( 3.4A);1N8 A 501 ( 3.6A);None;1N8 A 501 ( 3.3A);1N8 A 501 ( 3.3A)","0.65A","4v04A-2og8A:30.8","4v04A-2og8A:38.19"],["4V04_A_0LIA1772_1","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",6,"VAL A 596;ALA A 614;GLU A 633;LEU A 769;CYH A 774;HIS A 776","None","0.60A","4v04A-2ogvA:33.1","4v04A-2ogvA:47.87"],["4V04_A_0LIA1772_1","2ozo","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF00017(SH2);PF07714(Pkinase_Tyr)",6,"VAL A 352;ALA A 367;ALA A 417;LEU A 452;HIS A 459;GLY A 481","ANP A 615 (-4.5A);ANP A 615 (-3.3A);ANP A 615 (-3.9A);None;None;None","0.74A","4v04A-2ozoA:27.8","4v04A-2ozoA:21.50"],["4V04_A_0LIA1772_1","2p4i","Homo sapiens","ANGIOPOIETIN-1 RECEPTOR","PF07714(Pkinase_Tyr)",7,"VAL A 838;ALA A 853;ALA A 905;LEU A 955;HIS A 962;ALA A 981;ASP A 982","MR9 A 301 (-4.6A);MR9 A 301 (-3.5A);MR9 A 301 (-3.6A);MR9 A 301 (-4.4A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A)","0.55A","4v04A-2p4iA:25.4","4v04A-2p4iA:42.12"],["4V04_A_0LIA1772_1","2psq","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",10,"VAL A 495;ALA A 515;GLU A 534;MET A 537;VAL A 564;ALA A 567;LEU A 617;CYH A 622;HIS A 624;ALA A 643","None","0.65A","4v04A-2psqA:36.0","4v04A-2psqA:73.17"],["4V04_A_0LIA1772_1","2psq","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",8,"VAL A 495;ALA A 515;GLU A 534;VAL A 564;ALA A 567;HIS A 624;ALA A 643;GLY A 646","None","1.20A","4v04A-2psqA:36.0","4v04A-2psqA:73.17"],["4V04_A_0LIA1772_1","2qlu","Homo sapiens","ACTIVIN RECEPTOR TYPE IIB","PF00069(Pkinase)",6,"VAL A 204;ALA A 215;GLU A 230;LEU A 301;HIS A 319;ALA A 338","ADE A 488 ( 4.9A);ADE A 488 (-3.2A);None;None;None;None","0.95A","4v04A-2qluA:24.2","4v04A-2qluA:26.38"],["4V04_A_0LIA1772_1","2vk4","Kluyveromyces lactis","PYRUVATE DECARBOXYLASE","PF00205(TPP_enzyme_M);PF02775(TPP_enzyme_C);PF02776(TPP_enzyme_N)",6,"ALA A 218;GLU A 230;VAL A 285;ALA A 220;LEU A 189;ASP A 226","None","1.19A","4v04A-2vk4A:undetectable","4v04A-2vk4A:20.56"],["4V04_A_0LIA1772_1","2xik","Homo sapiens","SERINE\/THREONINE PROTEIN KINASE 25","PF00069(Pkinase)",6,"VAL A  34;ALA A  47;GLU A  66;LEU A 131;HIS A 138;ALA A 157","J60 A1294 ( 4.9A);J60 A1294 (-3.3A);None;None;None;J60 A1294 ( 4.2A)","0.63A","4v04A-2xikA:18.5","4v04A-2xikA:27.38"],["4V04_A_0LIA1772_1","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",7,"VAL A 261;ALA A 273;GLU A 290;HIS A 365;ALA A 384;ASP A 385;GLY A 387","None","1.41A","4v04A-2zv7A:30.7","4v04A-2zv7A:38.51"],["4V04_A_0LIA1772_1","3b2t","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",8,"VAL A 495;ALA A 515;GLU A 534;MET A 537;VAL A 564;ALA A 567;LEU A 617;CYH A 622","M33 A1996 ( 4.7A);M33 A1996 (-3.3A);None;None;None;M33 A1996 (-3.8A);None;None","0.91A","4v04A-3b2tA:27.9","4v04A-3b2tA:86.50"],["4V04_A_0LIA1772_1","3b2t","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"VAL A 495;ALA A 515;GLU A 534;VAL A 564;ALA A 567;HIS A 624;GLY A 646","M33 A1996 ( 4.7A);M33 A1996 (-3.3A);None;None;M33 A1996 (-3.8A);None;None","1.43A","4v04A-3b2tA:27.9","4v04A-3b2tA:86.50"],["4V04_A_0LIA1772_1","3b2t","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",8,"VAL A 495;ALA A 515;GLU A 534;VAL A 564;ALA A 567;LEU A 617;CYH A 622;HIS A 624","M33 A1996 ( 4.7A);M33 A1996 (-3.3A);None;None;M33 A1996 (-3.8A);None;None;None","0.78A","4v04A-3b2tA:27.9","4v04A-3b2tA:86.50"],["4V04_A_0LIA1772_1","3b2t","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",8,"VAL A 495;ALA A 515;MET A 537;VAL A 564;ALA A 567;LEU A 617;CYH A 622;ALA A 643","M33 A1996 ( 4.7A);M33 A1996 (-3.3A);None;None;M33 A1996 (-3.8A);None;None;None","0.77A","4v04A-3b2tA:27.9","4v04A-3b2tA:86.50"],["4V04_A_0LIA1772_1","3b2t","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"VAL A 495;ALA A 515;VAL A 564;ALA A 567;HIS A 624;ALA A 643;GLY A 646","M33 A1996 ( 4.7A);M33 A1996 (-3.3A);None;M33 A1996 (-3.8A);None;None;None","1.13A","4v04A-3b2tA:27.9","4v04A-3b2tA:86.50"],["4V04_A_0LIA1772_1","3b2t","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",8,"VAL A 495;ALA A 515;VAL A 564;ALA A 567;LEU A 617;CYH A 622;HIS A 624;ALA A 643","M33 A1996 ( 4.7A);M33 A1996 (-3.3A);None;M33 A1996 (-3.8A);None;None;None;None","0.52A","4v04A-3b2tA:27.9","4v04A-3b2tA:86.50"],["4V04_A_0LIA1772_1","3bhh","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE II BETA CHAIN","PF00069(Pkinase)",6,"VAL A  28;ALA A  41;GLU A  61;CYH A 127;HIS A 134;ALA A 156","5CP A 600 ( 4.4A);5CP A 600 (-3.6A);None;None;None;5CP A 600 ( 3.9A)","1.27A","4v04A-3bhhA:22.6","4v04A-3bhhA:26.67"],["4V04_A_0LIA1772_1","3c1x","Homo sapiens","HEPATOCYTE GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"ALA A1108;GLU A1127;LEU A1195;HIS A1202;ALA A1221;ASP A1222","CKK A1500 (-3.2A);CKK A1500 (-3.4A);CKK A1500 (-4.4A);CKK A1500 (-4.2A);CKK A1500 (-3.4A);CKK A1500 (-4.5A)","0.85A","4v04A-3c1xA:25.9","4v04A-3c1xA:32.30"],["4V04_A_0LIA1772_1","3c4f","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",11,"VAL A 492;ALA A 512;GLU A 531;MET A 534;VAL A 561;ALA A 564;LEU A 614;CYH A 619;HIS A 621;ALA A 640;GLY A 643","None;C4F A   1 (-3.3A);None;None;C4F A   1 ( 4.8A);C4F A   1 (-3.5A);None;None;None;C4F A   1 (-3.6A);None","0.55A","4v04A-3c4fA:42.7","4v04A-3c4fA:99.67"],["4V04_A_0LIA1772_1","3dak","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE OSR1","PF00069(Pkinase)",6,"VAL A  31;ALA A  44;LEU A 137;HIS A 144;ALA A 163;GLY A 166","ANP A   1 (-4.5A);ANP A   1 ( 3.9A);None;None; MG A 296 ( 3.9A);None","0.71A","4v04A-3dakA:21.3","4v04A-3dakA:30.46"],["4V04_A_0LIA1772_1","3e7o","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE 9","PF00069(Pkinase)",6,"VAL A  40;ALA A  53;GLU A  73;LEU A 142;HIS A 149;ASP A 169","35F A   1 ( 4.8A);35F A   1 (-3.6A);None;None;None;None","0.98A","4v04A-3e7oA:19.6","4v04A-3e7oA:25.72"],["4V04_A_0LIA1772_1","3hng","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",8,"VAL A 841;ALA A 859;GLU A 878;VAL A 909;LEU A1013;CYH A1018;HIS A1020;ASP A1040","8ST A2001 ( 4.6A);8ST A2001 ( 3.8A);8ST A2001 (-3.7A);8ST A2001 (-4.1A);8ST A2001 (-4.6A);8ST A2001 ( 4.7A);8ST A2001 ( 4.8A);None","0.60A","4v04A-3hngA:34.2","4v04A-3hngA:47.53"],["4V04_A_0LIA1772_1","3hu5","Desulfovibrio vulgaris","ISOCHORISMATASE FAMILY PROTEIN","PF00857(Isochorismatase)",6,"VAL A  56;ALA A  12;VAL A 131;ALA A  10;ALA A 147;ASP A 146","None","1.22A","4v04A-3hu5A:undetectable","4v04A-3hu5A:22.12"],["4V04_A_0LIA1772_1","3iec","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE MARK2","PF00069(Pkinase);PF00627(UBA)",7,"VAL A  67;ALA A  80;ALA A 132;HIS A 173;ALA A 192;ASP A 193;GLY A 195","None","1.35A","4v04A-3iecA:22.3","4v04A-3iecA:27.89"],["4V04_A_0LIA1772_1","3lm5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 17B","PF00069(Pkinase)",6,"VAL A  47;ALA A  60;GLU A  80;ALA A 113;LEU A 149;HIS A 156","QUE A   1 ( 4.6A);QUE A   1 (-3.2A);QUE A   1 (-3.1A);QUE A   1 (-3.9A);None;None","0.86A","4v04A-3lm5A:23.3","4v04A-3lm5A:23.73"],["4V04_A_0LIA1772_1","3mdy","Homo sapiens","BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B","PF07714(Pkinase_Tyr);PF08515(TGF_beta_GS)",6,"VAL A 218;ALA A 229;GLU A 244;HIS A 330;ALA A 349;GLY A 352","LDN A   1 ( 4.8A);LDN A   1 (-3.6A);None;None;LDN A   1 ( 3.8A);None","1.30A","4v04A-3mdyA:24.8","4v04A-3mdyA:26.05"],["4V04_A_0LIA1772_1","3mdy","Homo sapiens","BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B","PF07714(Pkinase_Tyr);PF08515(TGF_beta_GS)",6,"VAL A 218;ALA A 229;GLU A 244;LEU A 315;HIS A 330;ALA A 349","LDN A   1 ( 4.8A);LDN A   1 (-3.6A);None;None;None;LDN A   1 ( 3.8A)","0.90A","4v04A-3mdyA:24.8","4v04A-3mdyA:26.05"],["4V04_A_0LIA1772_1","3my0","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE RECEPTOR R3","PF07714(Pkinase_Tyr)",6,"VAL A 216;ALA A 227;HIS A 328;ALA A 347;ASP A 348;GLY A 350","LDN A 600 (-4.5A);LDN A 600 (-3.2A);None;LDN A 600 ( 3.8A);None;None","0.93A","4v04A-3my0A:24.1","4v04A-3my0A:30.35"],["4V04_A_0LIA1772_1","3my0","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE RECEPTOR R3","PF07714(Pkinase_Tyr)",6,"VAL A 216;ALA A 227;LEU A 313;HIS A 328;ALA A 347;ASP A 348","LDN A 600 (-4.5A);LDN A 600 (-3.2A);None;None;LDN A 600 ( 3.8A);None","1.12A","4v04A-3my0A:24.1","4v04A-3my0A:30.35"],["4V04_A_0LIA1772_1","3nuu","Homo sapiens","PKB-LIKE","PF00069(Pkinase)",6,"ALA A 109;GLU A 130;ALA A 162;HIS A 203;ASP A 223;GLY A 225","JOZ A 361 (-3.4A);SO4 A   5 (-3.1A);JOZ A 361 (-3.8A);None;SO4 A   5 ( 4.5A);SO4 A   5 ( 4.6A)","1.35A","4v04A-3nuuA:22.9","4v04A-3nuuA:26.45"],["4V04_A_0LIA1772_1","3nuu","Homo sapiens","PKB-LIKE","PF00069(Pkinase)",6,"VAL A  96;ALA A 109;GLU A 130;ALA A 162;HIS A 203;GLY A 225","JOZ A 361 ( 4.7A);JOZ A 361 (-3.4A);SO4 A   5 (-3.1A);JOZ A 361 (-3.8A);None;SO4 A   5 ( 4.6A)","1.17A","4v04A-3nuuA:22.9","4v04A-3nuuA:26.45"],["4V04_A_0LIA1772_1","3nuu","Homo sapiens","PKB-LIKE","PF00069(Pkinase)",6,"VAL A  96;ALA A 109;GLU A 130;ALA A 162;LEU A 196;HIS A 203","JOZ A 361 ( 4.7A);JOZ A 361 (-3.4A);SO4 A   5 (-3.1A);JOZ A 361 (-3.8A);None;None","0.71A","4v04A-3nuuA:22.9","4v04A-3nuuA:26.45"],["4V04_A_0LIA1772_1","3pls","Homo sapiens","MACROPHAGE-STIMULATING PROTEIN RECEPTOR","PF07714(Pkinase_Tyr)",6,"VAL A1096;ALA A1112;LEU A1199;HIS A1206;ALA A1225;GLY A1228","ANP A1358 (-4.4A);ANP A1358 ( 3.8A);None;None;None;None","0.72A","4v04A-3plsA:30.2","4v04A-3plsA:39.81"],["4V04_A_0LIA1772_1","3q4t","Homo sapiens","ACTIVIN RECEPTOR TYPE-2A","PF00069(Pkinase)",6,"VAL A 206;ALA A 217;GLU A 232;LEU A 303;HIS A 320;ALA A 339","TAK A   2 ( 4.9A);TAK A   2 (-3.5A);TAK A   2 ( 4.9A);None;None;TAK A   2 ( 4.2A)","1.01A","4v04A-3q4tA:23.6","4v04A-3q4tA:26.76"],["4V04_A_0LIA1772_1","3tt0","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",11,"VAL A 492;ALA A 512;GLU A 531;MET A 534;VAL A 561;ALA A 564;LEU A 614;CYH A 619;HIS A 621;ALA A 640;GLY A 643","07J A   1 (-4.0A);07J A   1 (-3.5A);07J A   1 (-3.8A);None;07J A   1 (-4.7A);07J A   1 (-3.8A);None;None;None;07J A   1 (-3.2A);None","0.56A","4v04A-3tt0A:41.1","4v04A-3tt0A:92.24"],["4V04_A_0LIA1772_1","3vid","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"VAL A 848;ALA A 866;GLU A 885;VAL A 916;LEU A1019;CYH A1024;ASP A1046","4TT A2001 ( 4.5A);4TT A2001 (-3.5A);None;None;None;None;None","0.75A","4v04A-3vidA:34.7","4v04A-3vidA:49.86"],["4V04_A_0LIA1772_1","3vid","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"VAL A 848;ALA A 866;GLU A 885;VAL A 916;LEU A1019;HIS A1026;ASP A1046","4TT A2001 ( 4.5A);4TT A2001 (-3.5A);None;None;None;None;None","0.47A","4v04A-3vidA:34.7","4v04A-3vidA:49.86"],["4V04_A_0LIA1772_1","3wzd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"VAL A 848;ALA A 866;GLU A 885;VAL A 916;LEU A1019;CYH A1024;HIS A1026","LEV A1201 ( 4.9A);LEV A1201 (-3.5A);LEV A1201 (-3.7A);LEV A1201 ( 4.6A);None;DTT A1202 (-2.0A);None","0.47A","4v04A-3wzdA:34.6","4v04A-3wzdA:54.81"],["4V04_A_0LIA1772_1","4agd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"VAL A 848;ALA A 866;GLU A 885;VAL A 916;LEU A1019;CYH A1024","None;B49 A2000 (-3.5A);None;B49 A2000 (-4.8A);None;None","0.82A","4v04A-4agdA:34.6","4v04A-4agdA:49.58"],["4V04_A_0LIA1772_1","4agd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"VAL A 848;ALA A 866;GLU A 885;VAL A 916;LEU A1019;HIS A1026;ASP A1046","None;B49 A2000 (-3.5A);None;B49 A2000 (-4.8A);None;None;None","0.71A","4v04A-4agdA:34.6","4v04A-4agdA:49.58"],["4V04_A_0LIA1772_1","4ckr","Homo sapiens","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"VAL A 624;ALA A 653;GLU A 672;LEU A 757;HIS A 764;ALA A 783;ASP A 784","DI1 A1000 (-4.8A);DI1 A1000 (-3.6A);DI1 A1000 (-3.8A);DI1 A1000 (-4.4A);DI1 A1000 (-3.8A);DI1 A1000 (-3.7A);DI1 A1000 (-4.1A)","0.66A","4v04A-4ckrA:30.6","4v04A-4ckrA:37.54"],["4V04_A_0LIA1772_1","4crs","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N2","PF00069(Pkinase);PF00433(Pkinase_C)",6,"VAL A 671;ALA A 684;GLU A 705;ALA A 740;ALA A 799;GLY A 802","AGS A1985 (-4.6A);AGS A1985 (-3.5A);None;AGS A1985 (-3.9A);AGS A1985 ( 4.5A);None","1.29A","4v04A-4crsA:15.0","4v04A-4crsA:28.57"],["4V04_A_0LIA1772_1","4crs","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N2","PF00069(Pkinase);PF00433(Pkinase_C)",6,"VAL A 671;ALA A 684;GLU A 705;ALA A 740;LEU A 773;ALA A 799","AGS A1985 (-4.6A);AGS A1985 (-3.5A);None;AGS A1985 (-3.9A);None;AGS A1985 ( 4.5A)","0.75A","4v04A-4crsA:15.0","4v04A-4crsA:28.57"],["4V04_A_0LIA1772_1","4e93","Homo sapiens","TYROSINE-PROTEIN KINASE FES\/FPS","PF00017(SH2);PF07714(Pkinase_Tyr)",6,"VAL A 575;ALA A 588;GLU A 607;LEU A 674;CYH A 679;HIS A 681","GUI A 901 (-4.5A);GUI A 901 (-3.4A);None;None;None;None","1.01A","4v04A-4e93A:32.1","4v04A-4e93A:33.25"],["4V04_A_0LIA1772_1","4f4p","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF07714(Pkinase_Tyr)",6,"VAL A 385;ALA A 400;GLU A 420;ALA A 451;HIS A 492;GLY A 514","0SB A 701 (-4.0A);0SB A 701 (-3.3A);None;0SB A 701 (-4.0A);None;None","1.32A","4v04A-4f4pA:25.9","4v04A-4f4pA:36.82"],["4V04_A_0LIA1772_1","4fl3","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF00017(SH2);PF07714(Pkinase_Tyr)",6,"VAL A 385;ALA A 400;ALA A 451;LEU A 485;HIS A 492;GLY A 514","ANP A 701 (-4.1A);ANP A 701 (-3.3A);ANP A 701 (-4.1A);None;None;None","0.88A","4v04A-4fl3A:29.1","4v04A-4fl3A:21.09"],["4V04_A_0LIA1772_1","4fr4","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 32A","PF00069(Pkinase)",6,"VAL A  37;ALA A  50;GLU A  71;VAL A 100;LEU A 137;HIS A 144","STU A 401 ( 4.9A);STU A 401 (-3.2A);None;None;None;None","0.79A","4v04A-4fr4A:13.2","4v04A-4fr4A:23.68"],["4V04_A_0LIA1772_1","4hvi","Homo sapiens","TYROSINE-PROTEIN KINASE JAK3","PF07714(Pkinase_Tyr)",7,"VAL A 836;ALA A 853;GLU A 871;LEU A 940;CYH A 945;HIS A 947;ALA A 966","19S A1201 (-4.4A);19S A1201 (-3.3A);None;None;None;None;19S A1201 ( 4.1A)","0.73A","4v04A-4hviA:29.2","4v04A-4hviA:35.52"],["4V04_A_0LIA1772_1","4k33","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 3","PF07714(Pkinase_Tyr)",7,"ALA A 506;VAL A 555;ALA A 558;HIS A 615;ALA A 634;ASP A 635;GLY A 637","ACP A 801 (-3.3A);ACP A 801 (-4.7A);ACP A 801 (-3.7A);None;None; MG A 802 ( 3.0A);None","1.36A","4v04A-4k33A:29.3","4v04A-4k33A:80.12"],["4V04_A_0LIA1772_1","4k33","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 3","PF07714(Pkinase_Tyr)",8,"VAL A 486;ALA A 506;GLU A 525;MET A 528;VAL A 555;ALA A 558;LEU A 608;ALA A 634","ACP A 801 (-4.2A);ACP A 801 (-3.3A);ACP A 801 ( 4.8A);None;ACP A 801 (-4.7A);ACP A 801 (-3.7A);None;None","0.82A","4v04A-4k33A:29.3","4v04A-4k33A:80.12"],["4V04_A_0LIA1772_1","4k33","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 3","PF07714(Pkinase_Tyr)",8,"VAL A 486;ALA A 506;GLU A 525;VAL A 555;ALA A 558;HIS A 615;ALA A 634;GLY A 637","ACP A 801 (-4.2A);ACP A 801 (-3.3A);ACP A 801 ( 4.8A);ACP A 801 (-4.7A);ACP A 801 (-3.7A);None;None;None","1.26A","4v04A-4k33A:29.3","4v04A-4k33A:80.12"],["4V04_A_0LIA1772_1","4k33","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 3","PF07714(Pkinase_Tyr)",8,"VAL A 486;ALA A 506;GLU A 525;VAL A 555;ALA A 558;LEU A 608;HIS A 615;ALA A 634","ACP A 801 (-4.2A);ACP A 801 (-3.3A);ACP A 801 ( 4.8A);ACP A 801 (-4.7A);ACP A 801 (-3.7A);None;None;None","0.70A","4v04A-4k33A:29.3","4v04A-4k33A:80.12"],["4V04_A_0LIA1772_1","4o27","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 24","PF00069(Pkinase)",6,"VAL B  38;ALA B  51;GLU B  70;HIS B 142;ALA B 161;GLY B 164","ADP B 500 (-4.5A);ADP B 500 (-3.3A);None;None;None;None","1.24A","4v04A-4o27B:24.2","4v04A-4o27B:28.61"],["4V04_A_0LIA1772_1","4o27","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 24","PF00069(Pkinase)",6,"VAL B  38;ALA B  51;GLU B  70;LEU B 135;HIS B 142;ALA B 161","ADP B 500 (-4.5A);ADP B 500 (-3.3A);None;None;None;None","0.60A","4v04A-4o27B:24.2","4v04A-4o27B:28.61"],["4V04_A_0LIA1772_1","4rt7","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",6,"VAL A 624;ALA A 642;GLU A 661;MET A 664;LEU A 802;CYH A 807","None;P30 A1001 (-3.4A);P30 A1001 (-3.6A);P30 A1001 ( 4.5A);None;None","0.96A","4v04A-4rt7A:28.4","4v04A-4rt7A:40.49"],["4V04_A_0LIA1772_1","4rt7","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",7,"VAL A 624;ALA A 642;GLU A 661;MET A 664;LEU A 802;HIS A 809;ASP A 829","None;P30 A1001 (-3.4A);P30 A1001 (-3.6A);P30 A1001 ( 4.5A);None;P30 A1001 ( 4.3A);None","0.84A","4v04A-4rt7A:28.4","4v04A-4rt7A:40.49"],["4V04_A_0LIA1772_1","4tr2","Plasmodium vivax","SUBTILISIN-LIKE 1 SERINE PROTEASE","PF00082(Peptidase_S8)",6,"ALA A 293;ALA A 528;LEU A 399;ALA A 557;ASP A 394;GLY A 395","None","1.26A","4v04A-4tr2A:undetectable","4v04A-4tr2A:19.49"],["4V04_A_0LIA1772_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",7,"VAL A  22;ALA A  35;GLU A  52;HIS A 127;ALA A 146;ASP A 147;GLY A 149","ACP A1264 (-4.7A);ACP A1264 (-2.9A);None;None;None;None;None","1.36A","4v04A-4ueuA:30.3","4v04A-4ueuA:41.10"],["4V04_A_0LIA1772_1","4uy9","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9","PF00069(Pkinase)",6,"VAL A 158;ALA A 169;ALA A 223;LEU A 256;HIS A 266;GLY A 296","None","0.72A","4v04A-4uy9A:26.7","4v04A-4uy9A:31.54"],["4V04_A_0LIA1772_1","4xcu","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 4","PF07714(Pkinase_Tyr)",10,"VAL A 481;ALA A 501;GLU A 520;VAL A 550;ALA A 553;LEU A 603;CYH A 608;HIS A 610;ALA A 629;GLY A 632","40M A1002 ( 4.5A);40M A1002 ( 4.1A);40M A1002 (-3.7A);40M A1002 (-4.7A);40M A1002 (-3.7A);None;None;None;40M A1002 (-3.0A);None","0.38A","4v04A-4xcuA:38.9","4v04A-4xcuA:73.40"],["4V04_A_0LIA1772_1","4xuf","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",7,"VAL A 624;ALA A 642;GLU A 661;MET A 664;LEU A 802;HIS A 809;ASP A 829","P30 A1001 ( 4.8A);P30 A1001 (-3.5A);P30 A1001 (-3.1A);P30 A1001 (-3.9A);None;P30 A1001 (-4.4A);None","0.69A","4v04A-4xufA:24.2","4v04A-4xufA:49.67"],["4V04_A_0LIA1772_1","4yff","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE TNNI3K","PF07714(Pkinase_Tyr)",6,"VAL A 477;ALA A 488;GLU A 509;LEU A 577;HIS A 586;ALA A 605","None;4CV A 801 (-3.5A);None;None;None;4CV A 801 ( 3.9A)","0.94A","4v04A-4yffA:24.6","4v04A-4yffA:28.94"],["4V04_A_0LIA1772_1","5a46","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","PF07714(Pkinase_Tyr)",11,"VAL A 492;ALA A 512;GLU A 531;MET A 534;VAL A 561;ALA A 564;LEU A 614;CYH A 619;HIS A 621;ALA A 640;GLY A 643","38O A1769 (-4.5A);38O A1769 (-3.6A);EDO A1766 (-4.1A);None;38O A1769 (-4.3A);38O A1769 (-3.9A);None;None;None;EDO A1766 ( 4.4A);EDO A1766 (-3.6A)","0.23A","4v04A-5a46A:43.5","4v04A-5a46A:98.08"],["4V04_A_0LIA1772_1","5dbx","Mus musculus","STE20\/SPS1-RELATED PROLINE-ALANINE-RICH PROTEIN KINASE","PF00069(Pkinase)",6,"VAL A  89;ALA A 102;LEU A 195;HIS A 202;ALA A 221;GLY A 224","ANP A 401 (-4.0A);ANP A 401 ( 4.0A);None;None; MG A 402 ( 4.6A);None","0.89A","4v04A-5dbxA:20.7","4v04A-5dbxA:28.02"],["4V04_A_0LIA1772_1","5es1","Homo sapiens","MAP\/MICROTUBULE AFFINITY-REGULATING KINASE 4","PF00069(Pkinase);PF00627(UBA)",6,"VAL A  70;ALA A  83;GLU A 103;ALA A 135;HIS A 176;ALA A 195","5RC A4000 (-4.6A);5RC A4000 (-3.6A);None;5RC A4000 (-3.7A);None;5RC A4000 ( 3.9A)","0.79A","4v04A-5es1A:22.4","4v04A-5es1A:28.73"],["4V04_A_0LIA1772_1","5fm2","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","PF07714(Pkinase_Tyr)",7,"VAL A 738;ALA A 756;GLU A 775;VAL A 804;ALA A 807;LEU A 865;HIS A 872","PP1 A2012 (-4.4A);PP1 A2012 (-3.2A);PP1 A2012 (-3.5A);PP1 A2012 (-4.5A);PP1 A2012 ( 3.5A);None;None","0.90A","4v04A-5fm2A:33.7","4v04A-5fm2A:51.53"],["4V04_A_0LIA1772_1","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",7,"VAL A 607;ALA A 625;GLU A 644;LEU A 809;CYH A 814;HIS A 816;ASP A 836","748 A1001 ( 4.7A);748 A1001 (-3.7A);748 A1001 (-3.3A);748 A1001 ( 4.6A);748 A1001 (-3.4A);748 A1001 (-3.8A);748 A1001 (-4.8A)","0.62A","4v04A-5grnA:25.8","4v04A-5grnA:46.09"],["4V04_A_0LIA1772_1","5hes","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT","PF07714(Pkinase_Tyr)",6,"VAL A  30;ALA A  43;ALA A  85;LEU A 121;HIS A 131;GLY A 153","032 A 401 (-4.4A);032 A 401 (-3.2A);032 A 401 (-3.6A);None;None;032 A 401 (-3.6A)","0.68A","4v04A-5hesA:25.7","4v04A-5hesA:30.59"],["4V04_A_0LIA1772_1","5hor","Homo sapiens","HEPATOCYTE GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"VAL A1092;ALA A1108;LEU A1195;HIS A1202;ALA A1221;GLY A1224","63K A1401 (-4.9A);63K A1401 (-3.5A);None;None;63K A1401 (-3.3A);None","0.83A","4v04A-5horA:26.0","4v04A-5horA:35.22"],["4V04_A_0LIA1772_1","5hu3","Drosophila melanogaster","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN","PF00069(Pkinase)",6,"VAL A  28;ALA A  41;GLU A  61;HIS A 134;ALA A 156;GLY A 159","ADP A 301 (-3.7A);ADP A 301 (-3.5A);None;None;ADP A 301 ( 4.8A);None","1.30A","4v04A-5hu3A:22.7","4v04A-5hu3A:24.62"],["4V04_A_0LIA1772_1","5idn","Homo sapiens","CYCLIN-DEPENDENT KINASE 8","PF00069(Pkinase)",7,"VAL A  35;ALA A  50;GLU A  66;ALA A 100;HIS A 149;ALA A 172;GLY A 175","6A7 A 401 ( 4.5A);6A7 A 401 (-3.3A);FMT A 404 ( 4.2A);6A7 A 401 (-3.7A);FMT A 403 (-4.6A);6A7 A 401 ( 4.1A);FMT A 404 ( 4.3A)","1.41A","4v04A-5idnA:15.5","4v04A-5idnA:26.20"],["4V04_A_0LIA1772_1","5idn","Homo sapiens","CYCLIN-DEPENDENT KINASE 8","PF00069(Pkinase)",7,"VAL A  35;ALA A  50;GLU A  66;ALA A 100;LEU A 142;HIS A 149;ALA A 172","6A7 A 401 ( 4.5A);6A7 A 401 (-3.3A);FMT A 404 ( 4.2A);6A7 A 401 (-3.7A);None;FMT A 403 (-4.6A);6A7 A 401 ( 4.1A)","0.81A","4v04A-5idnA:15.5","4v04A-5idnA:26.20"],["4V04_A_0LIA1772_1","5j5t","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3","PF00069(Pkinase)",6,"VAL A  30;ALA A  43;GLU A  61;LEU A 127;HIS A 134;ALA A 153","6G2 A 901 ( 4.9A);6G2 A 901 (-3.2A);None;None;None;6G2 A 901 ( 4.2A)","0.75A","4v04A-5j5tA:21.0","4v04A-5j5tA:24.94"],["4V04_A_0LIA1772_1","5j5t","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3","PF00069(Pkinase)",6,"VAL A  30;ALA A  43;GLU A  61;MET A  64;HIS A 134;ALA A 153","6G2 A 901 ( 4.9A);6G2 A 901 (-3.2A);None;None;None;6G2 A 901 ( 4.2A)","0.99A","4v04A-5j5tA:21.0","4v04A-5j5tA:24.94"],["4V04_A_0LIA1772_1","5x2v","Pseudomonas putida","L-METHIONINE GAMMA-LYASE","PF01053(Cys_Met_Meta_PP)",6,"VAL A 185;ALA A 160;LEU A 143;ALA A 167;ASP A 168;GLY A 171","None","1.25A","4v04A-5x2vA:undetectable","4v04A-5x2vA:21.36"],["4V04_A_0LIA1772_1","5xv7","Homo sapiens","SERINE-ARGININE (SR) PROTEIN KINASE 1","no annotation",6,"VAL A  94;ALA A 107;GLU A 124;HIS A 211;ALA A 496;GLY A 499","EMH A 705 ( 4.4A);EMH A 705 (-3.6A);None;None;EMH A 705 ( 4.0A);None","1.33A","4v04A-5xv7A:20.3","4v04A-5xv7A:13.31"],["4V04_A_0LIA1772_1","5xv7","Homo sapiens","SERINE-ARGININE (SR) PROTEIN KINASE 1","no annotation",6,"VAL A  94;ALA A 107;GLU A 124;LEU A 203;HIS A 211;ALA A 496","EMH A 705 ( 4.4A);EMH A 705 (-3.6A);None;None;None;EMH A 705 ( 4.0A)","0.65A","4v04A-5xv7A:20.3","4v04A-5xv7A:13.31"],["4V04_A_0LIA1772_1","6ao5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","no annotation",6,"VAL A  41;ALA A  54;LEU A 137;HIS A 144;ALA A 163;GLY A 166","ANP A 501 (-4.4A);ANP A 501 ( 3.7A);None;None;None;None","0.89A","4v04A-6ao5A:22.0","4v04A-6ao5A:24.81"],["4V04_A_0LIA1772_1","6b3e","Homo sapiens","CYCLIN-DEPENDENT KINASE 12","no annotation",6,"VAL A 741;ALA A 754;GLU A 774;CYH A 850;HIS A 857;ALA A 876","None;CJM A1102 (-3.1A);None;None;None;CJM A1102 (-3.6A)","1.17A","4v04A-6b3eA:22.1","4v04A-6b3eA:16.86"],["4V04_A_0LIA1772_1","6c9d","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE MARK1,SERINE\/THREONINE-PROTEIN KINASE MARK1","no annotation",7,"VAL A  74;ALA A  87;GLU A 107;ALA A 139;HIS A 180;ALA A 199;GLY A 202","None","1.33A","4v04A-6c9dA:21.2","4v04A-6c9dA:12.30"],["4V04_A_0LIA1772_1","6fek","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","no annotation",7,"VAL A 738;ALA A 756;GLU A 775;VAL A 804;ALA A 807;HIS A 872;GLY A 894","ADN A1104 (-4.4A);ADN A1104 (-3.4A);None;ADN A1104 ( 4.6A);ADN A1104 (-3.6A);None;None","1.45A","4v04A-6fekA:32.7","4v04A-6fekA:18.64"],["4V04_A_0LIA1772_1","6fek","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","no annotation",7,"VAL A 738;ALA A 756;GLU A 775;VAL A 804;ALA A 807;LEU A 865;HIS A 872","ADN A1104 (-4.4A);ADN A1104 (-3.4A);None;ADN A1104 ( 4.6A);ADN A1104 (-3.6A);None;None","0.78A","4v04A-6fekA:32.7","4v04A-6fekA:18.64"]]